- Report
- February 2024
- 170 Pages
Global
From €2220EUR$2,500USD£1,927GBP
- Report
- February 2024
- 112 Pages
Global
From €4219EUR$4,750USD£3,661GBP
- Report
- January 2023
- 153 Pages
North America
From €3064EUR$3,450USD£2,659GBP
- Report
- January 2023
- 170 Pages
Asia Pacific
From €3064EUR$3,450USD£2,659GBP
- Report
- February 2023
- 184 Pages
Global
From €3197EUR$3,600USD£2,775GBP
- Report
- February 2023
- 72 Pages
Asia Pacific
From €1332EUR$1,500USD£1,156GBP
- Report
- June 2025
- 70 Pages
From €3064EUR$3,450USD£2,659GBP
- Report
- October 2023
- 110 Pages
Global
From €3500EUR$4,221USD£3,143GBP
- Report
- October 2023
- 84 Pages
Global
From €3500EUR$4,221USD£3,143GBP
- Book
- February 2024
- 4864 Pages
- Book
- February 2023
- 256 Pages
- Book
- March 2022
- 640 Pages
- Book
- February 2022
- 1056 Pages
- Book
- December 2019
- 2656 Pages
- Book
- November 2019
- 416 Pages
- Book
- September 2019
- 280 Pages
- Book
- April 2016
- 4696 Pages
- Book
- December 2019
- 2656 Pages
- Book
- March 2019
- 552 Pages

Rosacea is a chronic skin condition that affects the face, characterized by redness, flushing, and visible blood vessels. It is estimated to affect up to 10% of the population, with women being more likely to be affected than men. Symptoms can range from mild to severe, and can be managed with lifestyle changes, topical treatments, and oral medications.
The global market for rosacea treatments is expected to grow significantly in the coming years, driven by increasing awareness of the condition, the availability of new treatments, and the growing demand for effective treatments. The market is segmented by product type, including topical treatments, oral medications, and laser treatments.
Some of the major companies in the rosacea market include Galderma, Allergan, Bayer, Pfizer, and Novartis. These companies are focused on developing new treatments and expanding their product portfolios to meet the growing demand for rosacea treatments. Show Less Read more